Royal London Asset Management Ltd. Sells 8,130 Shares of Medtronic PLC $MDT

Royal London Asset Management Ltd. cut its holdings in Medtronic PLC (NYSE:MDT) by 1.4% during the second quarter, Holdings Channel reports. The firm owned 577,485 shares of the medical technology company’s stock after selling 8,130 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Medtronic were worth $45,177,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mufg Securities Americas Inc. grew its holdings in Medtronic by 9.0% during the 2nd quarter. Mufg Securities Americas Inc. now owns 38,669 shares of the medical technology company’s stock valued at $3,025,000 after buying an additional 3,195 shares in the last quarter. Nissay Asset Management Corp Japan bought a new stake in shares of Medtronic during the second quarter valued at approximately $13,569,000. Chapin Davis Inc. lifted its holdings in shares of Medtronic by 41.9% in the second quarter. Chapin Davis Inc. now owns 3,898 shares of the medical technology company’s stock worth $305,000 after buying an additional 1,151 shares in the last quarter. Archer Investment Corp purchased a new position in shares of Medtronic in the second quarter worth $1,041,000. Finally, Pin Oak Investment Advisors Inc. bought a new position in shares of Medtronic during the second quarter worth $32,000. 82.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Jefferies Financial Group reiterated a “hold” rating and issued a $88.00 price target on shares of Medtronic in a research note on Thursday, June 4th. Wells Fargo & Company dropped their price objective on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, June 4th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. Eighteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $99.79.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. The firm reportedly expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance. Needham raises Medtronic price target
• Positive Sentiment: Analysts see potential for Medtronic to exceed consensus first-quarter expectations of approximately $1.39 in adjusted EPS and $9.54 billion in revenue. A stronger-than-expected report could support the shares, particularly if management lifts its fiscal 2027 outlook. Medtronic earnings estimates
• Positive Sentiment: Recent coverage highlights momentum in Medtronic’s cardiovascular businesses and growth in renal denervation, while broader device demand is supporting the company’s rebound narrative. Medtronic device momentum
• Neutral Sentiment: The imminent earnings release is likely to keep volatility elevated. Investors will evaluate quarterly performance, procedure trends, and management’s fiscal 2027 guidance for confirmation that the recovery is sustainable. Medtronic rebound outlook
• Negative Sentiment: Tariff exposure and unfavorable currency movements remain potential headwinds to margins and reported growth. These risks could limit the benefit of strong cardiovascular trends or weigh on the shares if management issues cautious guidance. Medtronic portfolio outlook

Medtronic Trading Up 1.5%

Shares of MDT opened at $91.28 on Friday. The stock has a market capitalization of $116.84 billion, a PE ratio of 24.47, a P/E/G ratio of 2.45 and a beta of 0.55. The company’s fifty day moving average is $85.57 and its 200 day moving average is $85.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. During the same quarter last year, the business earned $1.62 earnings per share. Medtronic’s quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Sell-side analysts expect that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio is currently 77.21%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).